Jana Rolff

1.1k total citations
20 papers, 722 citations indexed

About

Jana Rolff is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jana Rolff has authored 20 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jana Rolff's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Genomics and Diagnostics (3 papers) and Toxin Mechanisms and Immunotoxins (3 papers). Jana Rolff is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Genomics and Diagnostics (3 papers) and Toxin Mechanisms and Immunotoxins (3 papers). Jana Rolff collaborates with scholars based in Germany, United States and Netherlands. Jana Rolff's co-authors include Iduna Fichtner, Johannes Merk, Michael W. Becker, Jens Hoffmann, Anette Sommer, Stefanie Hammer, Richie Soong, Angelika Eggert, Gunda Leschber and Sebastian Jäger and has published in prestigious journals such as Nucleic Acids Research, PLoS ONE and Scientific Reports.

In The Last Decade

Jana Rolff

20 papers receiving 717 citations

Peers

Countries citing papers authored by Jana Rolff

Since Specialization

Citations

This map shows the geographic impact of Jana Rolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jana Rolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jana Rolff more than expected).

Fields of papers citing papers by Jana Rolff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jana Rolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jana Rolff. The network helps show where Jana Rolff may publish in the future.

Co-authorship network of co-authors of Jana Rolff

This figure shows the co-authorship network connecting the top 25 collaborators of Jana Rolff. A scholar is included among the top collaborators of Jana Rolff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jana Rolff. Jana Rolff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus 2021 ·Cancers ·Ana Textor, (unknown), (unknown), Anika Klaus, (unknown), Annika Winkler, (unknown), Jana Rolff, Anton G. Henssen, Uta E. Höpken, Angelika Eggert, Johannes H. Schulte, Michael C. Jensen, Thomas Blankenstein, Annette Künkele	28
2	Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma 2019 ·JCI Insight ·Ian C. MacArthur, Yi Bei, Heathcliff Dorado García, Michael V. Ortiz, Joern Toedling, Filippos Klironomos, Jana Rolff, Angelika Eggert, Johannes H. Schulte, Alex Kentsis, Anton G. Henssen	17
3	GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway 2018 ·Scientific Reports ·(unknown), (unknown), Jana Rolff, Sebastian Jäger, Angelika Eggert, (unknown), Georg Seifert	52
4	Synergistic Antitumour Properties ofviscumTTin Alveolar Rhabdomyosarcoma 2017 ·Journal of Immunology Research ·(unknown), (unknown), Jana Rolff, Sebastian Jäger, Angelika Eggert, Georg Seifert, (unknown)	7
5	Animal models for personalized treatment options 2017 ·International Journal of Clinical Pharmacology and Therapeutics ·Iduna Fichtner, Konrad Klinghammer, Diana Behrens, (unknown), Jana Rolff, Michael Becker, Annika Wulf-Goldenberg, (unknown), (unknown), (unknown), Burkhard Jandrig, Jens Hoffmann	5
6	Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma 2016 ·PLoS ONE ·(unknown), (unknown), Jana Rolff, Sebastian Jäger, Angelika Eggert, Georg Seifert, (unknown)	28
7	Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts 2016 ·Targeted Oncology ·Jana Rolff, Michael W. Becker, Johannes Merk, Jens Hoffmann, Iduna Fichtner	9
8	QSEA—modelling of genome-wide DNA methylation from sequencing enrichment experiments 2016 ·Nucleic Acids Research ·Matthias Lienhard, (unknown), Jana Rolff, Steffen Frese, Uwe Schirmer, Michael W. Becker, (unknown), Bernd Timmermann, Lukas Chávez, Holger Sültmann, Gunda Leschber, Iduna Fichtner, Michal R. Schweiger, Ralf Herwig	29
9	Investigation of cell culture volatilomes using solid phase micro extraction: Options and pitfalls exemplified with adenocarcinoma cell lines 2015 ·Journal of Chromatography B ·(unknown), Roland Becker, Christian Jung, Jana Rolff, Iduna Fichtner, Irene Nehls	29
10	A Natural Combination Extract of Viscum album L. Containing Both Triterpene Acids and Lectins Is Highly Effective against AML In Vivo 2015 ·PLoS ONE ·(unknown), (unknown), (unknown), (unknown), (unknown), Jana Rolff, Sebastian Jäger, Angelika Eggert, Georg Seifert	42
11	In vitro cultured lung cancer cells are not suitable for animal-based breath biomarker detection 2015 ·Journal of Breath Research ·(unknown), Roland Becker, (unknown), Randolf Menzel, (unknown), Carola Fischer‐Tenhagen, Jana Rolff, Irene Nehls	27
12	Predictive In Vivo Models for Oncology 2015 ·Handbook of experimental pharmacology ·Diana Behrens, Jana Rolff, Jens Hoffmann	7
13	Insight into mistletoe´s mechanism of action of targeting pediatric Ewing Sarcoma 2015 ·Phytomedicine ·(unknown), (unknown), Sebastian Jäger, Jana Rolff, Angelika Eggert, Georg Seifert, (unknown)	1
14	Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib 2014 ·Lung Cancer ·(unknown), Jana Rolff, Christian Bender, Mostafa Jarahian, Ulrike Korf, Ralf Herwig, Holger Fröhlich, Michael Thomas, Johannes Merk, Iduna Fichtner, Holger Sültmann, Ruprecht Kuner	14
15	Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? 2011 ·European Journal of Cardio-Thoracic Surgery ·Johannes Merk, Jana Rolff, (unknown), Gunda Leschber, Iduna Fichtner	35
16	Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer 2010 ·Clinical Cancer Research ·Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael W. Becker, Jana Rolff, Johannes Merk, Ulrich Klar, Jens Hoffmann	34
17	Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?☆ 2009 ·European Journal of Cardio-Thoracic Surgery ·Johannes Merk, Jana Rolff, Michael W. Becker, Gunda Leschber, Iduna Fichtner	51
18	Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies 2009 ·British Journal of Cancer ·(unknown), Jana Rolff, M Lemm, Iduna Fichtner, Rolando Pérez, Enrique Montero	68
19	Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers 2009 ·Journal of Oncology ·Jana Rolff, (unknown), Johannes Merk, Iduna Fichtner	12
20	Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers 2008 ·Clinical Cancer Research ·Iduna Fichtner, Jana Rolff, Richie Soong, Jens Hoffmann, Stefanie Hammer, Anette Sommer, Michael W. Becker, Johannes Merk	227

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact